Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 190 articles: HTML format

Single Articles

November 2026
1. MELLE-HANNAH M, Kjolhede H, Backdahl H, Johansson ME, et al
   First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument.
   BJU Int. 2026;138:867-876.
   PubMed     Abstract available
   
   
   
2. LEHNER F, Dugas S, Birkhauser V, Gross O, et al
   Bladder washing cytology in the initial evaluation of patients with neuro-urological disorders: to do or not to do?
   BJU Int. 2026;138:860-866.
   PubMed     Abstract available
   
   
   
3. MUNK L, Hyldgaard JM, Kumasegaram V, Milling RV, et al
   Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial.
   BJU Int. 2026;138:831-840.
   PubMed     Abstract available
   
   
   October 2026
4. DEPALMA M, Rossi F, Ferro M, Bukavina L, et al
   Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer: efficacy proven, duration unclear.
   BJU Int. 2026 Oct 21. doi: 10.1111/bju.70507.
   PubMed    
   
   
   
5. WANG J, Zhao Y, Ye Y, Qi X, et al
   Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.
   BJU Int. 2026 Oct 11. doi: 10.1111/bju.70488.
   PubMed     Abstract available
   
   
   
6. ESCRIG JLD, Black P, Inokuchi J, Kulkarni G, et al
   Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.
   BJU Int. 2026 Oct 2. doi: 10.1111/bju.70480.
   PubMed     Abstract available
   
   
   
7. CONNOR MJ, Gopalakrishnan A, Mayor N, Bolton E, et al
   Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).
   BJU Int. 2026;138:705-713.
   PubMed     Abstract available
   
   
   
8. CONTIERI R, van Rhijn BWG, Cathomas R, Lorch A, et al
   Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
   BJU Int. 2026;138:558-564.
   PubMed     Abstract available
   
   
   
9. GABRIEL PE, Zhu A, Karim CG, Eraky A, et al
   Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.
   BJU Int. 2026;138:640-649.
   PubMed     Abstract available
   
   
   September 2026
10. TOUMAZOS K, Bell S, Spencer K, Nakagawa D, et al
    Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
    BJU Int. 2026 Sep 28. doi: 10.1111/bju.70461.
    PubMed     Abstract available
    
    
    
11. HURLE R, Contieri R, Sormani F, Lazzeri M, et al
    Quality of life in patients on active surveillance for bladder cancer.
    BJU Int. 2026 Sep 9. doi: 10.1111/bju.70449.
    PubMed    
    
    
    
12. IBRAHIM Y, Ribeiro L, Spazzapan M, Gad M, et al
    Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.
    BJU Int. 2026;138:449-455.
    PubMed     Abstract available
    
    
    August 2026
13. MIYAJIMA K, Miszczyk M, Roessler N, Inoue S, et al
    Diet and risk of bladder cancer: a systematic review of epidemiological evidence.
    BJU Int. 2026 Aug 23. doi: 10.1111/bju.70435.
    PubMed     Abstract available
    
    
    
14. CELLA L, Contieri R, Paciotti M, Fasulo V, et al
    Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.
    BJU Int. 2026 Aug 17. doi: 10.1111/bju.70404.
    PubMed     Abstract available
    
    
    
15. CHEN Y, Yue Z
    Incidence is not surveillance yield: interpreting metachronous upper tract urothelial carcinoma risk after non-muscle-invasive bladder cancer.
    BJU Int. 2026 Aug 11. doi: 10.1111/bju.70429.
    PubMed    
    
    
    July 2026
16. LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
    INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
    BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
    PubMed     Abstract available
    
    
    
17. DUAN Q
    Letter to the Editor regarding: reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Jul 17. doi: 10.1111/bju.70385.
    PubMed    
    
    
    
18. GHALI F, Tan WS
    A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 3. doi: 10.1111/bju.70377.
    PubMed    
    
    
    
19. AYDOGDU C, Wang B, McSweeney ST, Diaz G, et al
    Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 2. doi: 10.1111/bju.70376.
    PubMed     Abstract available
    
    
    
20. NOLAZCO JI, Melnick KR, Lee RJ, Efstathiou JA, et al
    Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.
    BJU Int. 2026;138:22-32.
    PubMed     Abstract available
    
    
    
21. ORECCHIA L, Gerardi M, Colalillo G, Leonardis F, et al
    Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
    BJU Int. 2026;138:92-99.
    PubMed     Abstract available
    
    
    June 2026
22. UROLAGIN D, Sowmya BA, Kavyashree MV
    Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 10. doi: 10.1111/bju.70296.
    PubMed    
    
    
    
23. VAN HATTUM JW, Remmelink MJ, Oddens JR, de Reijke TM, et al
    Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 9. doi: 10.1111/bju.70295.
    PubMed    
    
    
    
24. CONTIERI R, Martini A, Furrer M, D'Andrea D, et al
    Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
    BJU Int. 2026;137:1058-1066.
    PubMed     Abstract available
    
    
    
25. DIANA P, Di Bello F, Mas L, Gallioli A, et al
    Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.
    BJU Int. 2026;137:1026-1031.
    PubMed     Abstract available
    
    
    
26. SOPUTRO NA, Wang L, Daher K, Al-Bayati A, et al
    Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.
    BJU Int. 2026;138 Suppl 1:S49-S55.
    PubMed     Abstract available
    
    
    May 2026
27. ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
    Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
    BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
    PubMed     Abstract available
    
    
    
28. TILLU N, Wiklund P
    Response to: 'Comment on long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 11. doi: 10.1111/bju.70312.
    PubMed    
    
    
    
29. CHETHAN GS, Patil NS
    Comment on 'Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 7. doi: 10.1111/bju.70313.
    PubMed    
    
    
    April 2026
30. PACKIAM VT, Black PC, Catto JWF, Ghodoussipour S, et al
    'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.
    BJU Int. 2026 Apr 28. doi: 10.1111/bju.70299.
    PubMed    
    
    
    
31. VAN HOOGSTRATEN LMC, Vermeulen SH, Hof JP, van der Heijden AG, et al
    Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70297.
    PubMed     Abstract available
    
    
    
32. ZHANG B, Wang C, Shang P
    Comment on 'Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach'.
    BJU Int. 2026 Apr 23. doi: 10.1111/bju.70302.
    PubMed    
    
    
    
33. FU MZ, Packiam VT, Byrne J
    Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
    PubMed    
    
    
    
34. KUMAR V, Kant R
    Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
    PubMed    
    
    
    
35. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
    PubMed     Abstract available
    
    
    
36. SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
    Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
    PubMed     Abstract available
    
    
    
37. BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
    Is there still a role for ureteric frozen section analysis during radical cystectomy?
    BJU Int. 2026;137:659-666.
    PubMed     Abstract available
    
    
    
38. DAY E, Bizzarri FP, Waine E, Martin R, et al
    Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
    BJU Int. 2026;137:708-715.
    PubMed     Abstract available
    
    
    
39. PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
    Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
    BJU Int. 2026;137:684-689.
    PubMed     Abstract available
    
    
    March 2026
40. HJORT PB, Jensen JB, Ernst A
    Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
    PubMed     Abstract available
    
    
    
41. YE T, Tura B, Abbotts B, Zeegers MP, et al
    Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
    BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
    PubMed    
    
    
    
42. SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
    Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
    PubMed     Abstract available
    
    
    
43. 
    Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
    PubMed    
    
    
    
44. SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
    Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
    BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
    PubMed    
    
    
    
45. ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
    Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
    BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
    PubMed     Abstract available
    
    
    
46. BRYAN RT, Patel K, Ward DG
    The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
    PubMed    
    
    
    
47. FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
    Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
    PubMed     Abstract available
    
    
    
48. AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
    Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
    BJU Int. 2026;137:536-546.
    PubMed     Abstract available
    
    
    February 2026
49. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
    Aligning bladder cancer research with patient needs: an update on research priorities.
    BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
    PubMed    
    
    
    
50. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
    Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
    PubMed     Abstract available
    
    
    
51. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
    Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
    BJU Int. 2026;137:323-331.
    PubMed     Abstract available
    
    
    
52. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
    Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
    BJU Int. 2026;137:270-281.
    PubMed     Abstract available
    
    
    January 2026
53. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
    BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
    PubMed     Abstract available
    
    
    
54. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
    Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
    PubMed     Abstract available
    
    
    
55. DI BELLO F, Gallioli A, Cannoletta D, Mancon S, et al
    Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis.
    BJU Int. 2026;137:26-35.
    PubMed     Abstract available
    
    
    
56. MIEDERER M, Pretze M, Abbate E, Hartig A, et al
    Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
    BJU Int. 2026;137:166-172.
    PubMed     Abstract available
    
    
    December 2025
57. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
    Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
    PubMed     Abstract available
    
    
    
58. MENNES J, Akand M, Benijts R, Baekelandt L, et al
    Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
    PubMed     Abstract available
    
    
    November 2025
59. 
    Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
    BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
    PubMed    
    
    
    
60. PACE KJC, Kwong JCC, Randhawa H, Ringa M, et al
    Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 19. doi: 10.1111/bju.70085.
    PubMed     Abstract available
    
    
    
61. ABDULMAJEED A, Bekiroglu F, Aydin A, Laguna P, et al
    Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants.
    BJU Int. 2025 Nov 18. doi: 10.1111/bju.70079.
    PubMed     Abstract available
    
    
    
62. RHODES AC, McClintic KA, Witt E, Nwosu I, et al
    Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 3. doi: 10.1111/bju.70060.
    PubMed     Abstract available
    
    
    
63. BRANDT SB, Korner SK, Milling RV, Nielsen NK, et al
    Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
    BJU Int. 2025;136:858-865.
    PubMed     Abstract available
    
    
    
64. MASTROIANNI R, Chiacchio G, Tuderti G, Brassetti A, et al
    Stapled vs totally handsewn robotic intracorporeal neobladder: perioperative and functional outcomes.
    BJU Int. 2025;136:866-871.
    PubMed     Abstract available
    
    
    October 2025
65. MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al
    Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Oct 22. doi: 10.1111/bju.70044.
    PubMed     Abstract available
    
    
    
66. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
    Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
    BJU Int. 2025;136:728-737.
    PubMed     Abstract available
    
    
    
67. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
    BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
    PubMed     Abstract available
    
    
    
68. PAYNTER JA, Doherty Z, Qin KR, Pilcher D, et al
    Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions.
    BJU Int. 2025;136 Suppl 2.
    PubMed     Abstract available
    
    
    September 2025
69. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
    Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
    PubMed     Abstract available
    
    
    
70. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
    Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
    BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
    PubMed     Abstract available
    
    
    
71. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    PubMed     Abstract available
    
    
    
72. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
    Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
    BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
    PubMed     Abstract available
    
    
    August 2025
73. ZAURITO P, Scilipoti P, Longoni M, Viti A, et al
    The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
    PubMed     Abstract available
    
    
    
74. DEY L, Rautiola J, Akre O, Egevad L, et al
    Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
    PubMed     Abstract available
    
    
    
75. DE ANGELIS M, Scilipoti P, Santangelo A, Longoni M, et al
    The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates.
    BJU Int. 2025;136:336-343.
    PubMed     Abstract available
    
    
    
76. BEN-DAVID R, Pellegrino F, Mehrazin R, Thomas J, et al
    Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy.
    BJU Int. 2025;136:321-328.
    PubMed     Abstract available
    
    
    July 2025
77. LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al
    Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
    PubMed    
    
    
    
78. HOF J, Vermeulen S, Richters A
    Biased associations between number of BCG instillations and outcome in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866.
    PubMed    
    
    
    
79. VON DEIMLING M, Furrer M, Bianchi A, Pichler R, et al
    Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer.
    BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851.
    PubMed     Abstract available
    
    
    
80. TEMPO J, Felemban S, Qin KR, Perera M, et al
    Radical cystectomy mortality in older patients: a systematic review and meta-analysis.
    BJU Int. 2025;136:19-31.
    PubMed     Abstract available
    
    
    June 2025
81. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    PubMed     Abstract available
    
    
    
82. FERRO M, Catellani M, Bianchi R, Fallara G, et al
    Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828.
    PubMed     Abstract available
    
    
    
83. ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al
    Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel.
    BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827.
    PubMed     Abstract available
    
    
    
84. HANEY CM, Studier-Fischer A, Geissler ME, Ohlmeier J, et al
    Indocyanine-guided ureter resection for radical cystectomy - a systematic review and meta-analysis.
    BJU Int. 2025;135:908-917.
    PubMed     Abstract available
    
    
    
85. AMPARORE D, De Cillis S, Colombo M, Garzena V, et al
    TYTOCARE home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
    BJU Int. 2025;135:960-968.
    PubMed     Abstract available
    
    
    May 2025
86. KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al
    Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
    BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
    PubMed     Abstract available
    
    
    
87. VAN HATTUM JW, Remmelink MJ, Nuijens ST, de Ruiter BM, et al
    A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer.
    BJU Int. 2025 May 22. doi: 10.1111/bju.16767.
    PubMed     Abstract available
    
    
    
88. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
    Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.
    BJU Int. 2025 May 21. doi: 10.1111/bju.16780.
    PubMed     Abstract available
    
    
    
89. BOSVELD J, Nguyen TQ, Boormans JL, Witjes JA, et al
    The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.
    BJU Int. 2025;135:766-774.
    PubMed     Abstract available
    
    
    April 2025
90. NUIJENS ST, van Hoogstraten LMC, Terpstra NB, Beeren I, et al
    The impact of treatment for muscle-invasive bladder cancer on health-related quality of life.
    BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736.
    PubMed     Abstract available
    
    
    
91. BRYAN RT, Patel P, Kennish SJ, Catto JWF, et al
    Improving the pathway to correct treatment for patients with muscle-invasive bladder cancer: exploring the myths around the BladderPath trial.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728.
    PubMed    
    
    
    March 2025
92. COLLETT G, Bashford T, Whitehead NJ, Kazimierska E, et al
    Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army.
    BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
    PubMed    
    
    
    
93. TREVISANI F, Floris M, Longoni M, Rosiello G, et al
    Acute kidney disease after radical cystectomy for bladder cancer: a new onco-nephrological view.
    BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
    PubMed     Abstract available
    
    
    
94. ROLDAN FL, Ingelmo-Torres M, Mercader C, Figueras M, et al
    Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16697.
    PubMed     Abstract available
    
    
    
95. CHOWDHURY D, Apolo AB, Jiang DM, Skinner EC, et al
    Understanding patient perspectives in the management of their muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16695.
    PubMed     Abstract available
    
    
    
96. RAUTIOLA J, Bjorklund J, Ben-David R, Skokic V, et al
    Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer.
    BJU Int. 2025 Mar 4. doi: 10.1111/bju.16691.
    PubMed     Abstract available
    
    
    
97. 
    Advances in the management of high-risk localised muscle invasive bladder cancer.
    BJU Int. 2025;135:364-365.
    PubMed    
    
    
    
98. STRUCK JP, Moharam N, Leitenberger A, Weber J, et al
    An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.
    BJU Int. 2025;135:446-455.
    PubMed     Abstract available
    
    
    
99. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes.
    BJU Int. 2025;135:473-480.
    PubMed     Abstract available
    
    
    February 2025
100. TILLU N, Ben-David R, Skokic V, Rich JM, et al
     Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
     BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
     PubMed     Abstract available
     
     
     
101. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
     Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
     BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
     PubMed     Abstract available
     
     
     January 2025
102. BEEREN I, Meijer H, van der Heijden AG, Aben KKH, et al
     Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
     BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
     PubMed     Abstract available
     
     
     
103. KLUGER N, van der van der Bent SAS
     Tattoos as a risk factor for bladder cancer: a call for cohort studies.
     BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
     PubMed    
     
     
     
104. OLAH C, Sichward L, Hadaschik B, Darr C, et al
     Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
     BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
     PubMed     Abstract available
     
     
     
105. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
     Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
     BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
     PubMed     Abstract available
     
     
     
106. PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
     National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
     BJU Int. 2025;135:140-147.
     PubMed     Abstract available
     
     
     
107. JOHN JB, Collins M, Eames S, O'Flynn K, et al
     The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
     BJU Int. 2025;135:78-87.
     PubMed     Abstract available
     
     
     December 2024
108. LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
     Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
     BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
     PubMed     Abstract available
     
     
     
109. HAILE ES, Lone Z, Shin D, Nowacki AS, et al
     Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
     BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
     PubMed     Abstract available
     
     
     
110. PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
     International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
     BJU Int. 2024;134:932-938.
     PubMed     Abstract available
     
     
     
111. GUO AA, Zeng K, Bushati Y, Kim P, et al
     Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
     BJU Int. 2024;134 Suppl 2:22-29.
     PubMed     Abstract available
     
     
     
112. AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
     Long-term quality of life in patients with bladder cancer following radical cystectomy.
     BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
     PubMed     Abstract available
     
     
     November 2024
113. LONE Z, Shin D, Nowacki A, Campbell RA, et al
     Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
     BJU Int. 2024;134:841-847.
     PubMed     Abstract available
     
     
     
114. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
     A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
     BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
     PubMed     Abstract available
     
     
     October 2024
115. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
     Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
     BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
     PubMed     Abstract available
     
     
     
116. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
     Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.
     BJU Int. 2024 Oct 21. doi: 10.1111/bju.16565.
     PubMed     Abstract available
     
     
     
117. DEL GIUDICE F, Vestri A, Fegatelli DA, Husch T, et al
     VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
     BJU Int. 2024 Oct 13. doi: 10.1111/bju.16531.
     PubMed     Abstract available
     
     
     
118. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
     Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
     BJU Int. 2024;134:541-550.
     PubMed     Abstract available
     
     
     
119. RIEGER C, Schluchtermann J, Storz E, Kastner L, et al
     Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
     BJU Int. 2024;134:582-588.
     PubMed     Abstract available
     
     
     September 2024
120. CONROY S, Jubber I, Noon AP, Rosario DJ, et al
     Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
     BJU Int. 2024 Sep 26. doi: 10.1111/bju.16516.
     PubMed     Abstract available
     
     
     
121. LIU K, Nicoletti R, Zhao H, Chen X, et al
     The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
     BJU Int. 2024 Sep 10. doi: 10.1111/bju.16493.
     PubMed     Abstract available
     
     
     
122. VACCARO C, Dewulf K, Richter K, Branger N, et al
     Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique.
     BJU Int. 2024;134:501-503.
     PubMed    
     
     
     
123. ZENNAMI K, Kusaka M, Tomozawa S, Toda F, et al
     Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion.
     BJU Int. 2024;134:426-433.
     PubMed     Abstract available
     
     
     
124. D'ANDREA D, Soria F, Moschini M, Laukhtina E, et al
     Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy.
     BJU Int. 2024;134:459-464.
     PubMed     Abstract available
     
     
     
125. AFFERI L, Spahn M, Hayoz S, Strebel RT, et al
     Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
     BJU Int. 2024;134:388-397.
     PubMed     Abstract available
     
     
     August 2024
126. SU ZT, Florissi IS, Mahon KM, Li T, et al
     Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer.
     BJU Int. 2024 Aug 29. doi: 10.1111/bju.16521.
     PubMed     Abstract available
     
     
     
127. TAYLOR JI, Kamat AM, O'Donnell MA, Annapureddy D, et al
     Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
     BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509.
     PubMed     Abstract available
     
     
     
128. HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
     Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
     BJU Int. 2024;134:229-238.
     PubMed     Abstract available
     
     
     
129. MATSUDA A, Taoka R, Miki J, Saito R, et al
     Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
     BJU Int. 2024;134:207-218.
     PubMed     Abstract available
     
     
     July 2024
130. CHAKRA MA, Lassila R, El Beayni N, Mott SL, et al
     Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
     BJU Int. 2024 Jul 31. doi: 10.1111/bju.16486.
     PubMed     Abstract available
     
     
     
131. REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
     Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
     BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
     PubMed     Abstract available
     
     
     
132. ANTONELLI L, Wendel-Garcia PD, Deforth M, Afferi L, et al
     Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
     BJU Int. 2024 Jul 3. doi: 10.1111/bju.16444.
     PubMed     Abstract available
     
     
     
133. 
     Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
     BJU Int. 2024;134:4-5.
     PubMed    
     
     
     
134. PELLEGRINO F, Scilipoti P, Rosiello G, Longoni M, et al
     Long-term functional outcomes after robot-assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
     BJU Int. 2024;134:48-50.
     PubMed    
     
     
     
135. TUDERTI G, Mastroianni R, Anceschi U, Bove AM, et al
     Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series.
     BJU Int. 2024;134:103-109.
     PubMed     Abstract available
     
     
     
136. MYERS AA, Tan WS, de Groot J, Westney OL, et al
     'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder.
     BJU Int. 2024;134:45-47.
     PubMed    
     
     
     
137. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
     Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
     BJU Int. 2024;134:43-44.
     PubMed    
     
     
     
138. AN X, Xue C, Chen M, Ni M, et al
     Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
     BJU Int. 2024;134:63-71.
     PubMed     Abstract available
     
     
     June 2024
139. WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
     Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
     BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
     PubMed     Abstract available
     
     
     
140. FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
     Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
     BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
     PubMed     Abstract available
     
     
     
141. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
     How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
     BJU Int. 2024;133:673-677.
     PubMed    
     
     
     May 2024
142. FINOCCHIARO A, Paciotti M, Contieri R, Fasulo V, et al
     Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
     BJU Int. 2024 May 22. doi: 10.1111/bju.16406.
     PubMed    
     
     
     
143. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
     Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
     BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
     PubMed     Abstract available
     
     
     April 2024
144. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
     Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
     BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
     PubMed     Abstract available
     
     
     
145. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
     Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
     BJU Int. 2024 Apr 24. doi: 10.1111/bju.16364.
     PubMed     Abstract available
     
     
     
146. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
     Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
     BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
     PubMed     Abstract available
     
     
     
147. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
     Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
     PubMed     Abstract available
     
     
     
148. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
     Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
     PubMed     Abstract available
     
     
     
149. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
     Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
     BJU Int. 2024;133:474-479.
     PubMed     Abstract available
     
     
     
150. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
     Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
     BJU Int. 2024;133 Suppl 4:53-63.
     PubMed     Abstract available
     
     
     
151. BOTROS A, Rival PM, Page F, Davis ID, et al
     Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
     BJU Int. 2024;133 Suppl 4:7-10.
     PubMed    
     
     
     March 2024
152. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
     Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
     BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
     PubMed     Abstract available
     
     
     
153. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
     The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
     PubMed     Abstract available
     
     
     
154. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
     The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
     PubMed     Abstract available
     
     
     February 2024
155. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
     A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
     BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
     PubMed     Abstract available
     
     
     
156. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
     Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
     BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
     PubMed     Abstract available
     
     
     
157. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
     Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
     BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
     PubMed     Abstract available
     
     
     
158. 
     Significant advances in chemotherapy for both urothelial and renal cancer.
     BJU Int. 2024;133:122-123.
     PubMed    
     
     
     
159. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
     Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
     BJU Int. 2024;133:154-157.
     PubMed    
     
     
     January 2024
160. LU SM, Zhang Y, Dong XT, Wang JL, et al
     Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
     BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
     PubMed    
     
     
     
161. YIM A, Alberto M, Sharma V, Green A, et al
     Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
     BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
     PubMed     Abstract available
     
     
     December 2023
162. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
     Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
     BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
     PubMed     Abstract available
     
     
     
163. HACK J, Douglas J, Makaroff L, Costin M, et al
     Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
     PubMed    
     
     
     
164. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
     Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
     BJU Int. 2023;132:671-677.
     PubMed     Abstract available
     
     
     November 2023
165. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
     Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
     BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
     PubMed     Abstract available
     
     
     
166. CHEDGY ECP, Tang R, Struss WJ, Lowe G, et al
     A randomized controlled trial investigating rectus sheath catheters following radical cystectomy.
     BJU Int. 2023;132:554-559.
     PubMed     Abstract available
     
     
     October 2023
167. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
     Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
     BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
     PubMed     Abstract available
     
     
     
168. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
     Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
     BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
     PubMed    
     
     
     
169. NECCHI A, Basile G, Gibb EA, Raggi D, et al
     VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
     BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
     PubMed     Abstract available
     
     
     
170. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
     Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
     BJU Int. 2023;132:428-434.
     PubMed     Abstract available
     
     
     September 2023
171. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
     Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
     BJU Int. 2023;132:291-297.
     PubMed     Abstract available
     
     
     August 2023
172. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
     Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
     BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
     PubMed     Abstract available
     
     
     July 2023
173. CONTIERI R, Grajales V, Tan WS, Martini A, et al
     Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
     BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
     PubMed     Abstract available
     
     
     
174. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
     Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
     BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
     PubMed     Abstract available
     
     
     
175. 
     Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
     BJU Int. 2023;132:2-3.
     PubMed    
     
     
     
176. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
     Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
     BJU Int. 2023;132:84-91.
     PubMed     Abstract available
     
     
     June 2023
177. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
     Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
     BJU Int. 2023;131:691-693.
     PubMed    
     
     
     
178. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
     Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
     BJU Int. 2023;131:734-744.
     PubMed     Abstract available
     
     
     
179. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
     Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
     BJU Int. 2023;131:755-762.
     PubMed     Abstract available
     
     
     
180. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
     Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
     BJU Int. 2023;131:712-719.
     PubMed     Abstract available
     
     
     May 2023
181. TAN WS, Grajales V, Bree K, Li R, et al
     BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
     BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
     PubMed    
     
     
     
182. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
     Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
     BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
     PubMed     Abstract available
     
     
     
183. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
     Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
     BJU Int. 2023;131:571-580.
     PubMed     Abstract available
     
     
     April 2023
184. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
     Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
     BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
     PubMed    
     
     
     
185. FREGO N, Contieri R, Diana P, Mancon S, et al
     Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
     BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
     PubMed    
     
     
     
186. ROSE KM, Narang G, Rosen G, Labatte C, et al
     Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
     BJU Int. 2023;131:471-476.
     PubMed     Abstract available
     
     
     
187. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
     Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
     BJU Int. 2023;131:477-485.
     PubMed     Abstract available
     
     
     March 2023
188. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
     Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
     BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
     PubMed     Abstract available
     
     
     
189. BESIROGLU H
     Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
     BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
     PubMed    
     
     
     
190. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
     Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
     BJU Int. 2023;131:306-312.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum